Oncology & Cancer

Roche targets tumours with Ignyta purchase

Roche, the world's top cancer drug maker, announced Friday it had agreed to buy US firm Ignyta, which is developing a treatment against some tumours, for $1.7 billion (1.4 billion euros).

Oncology & Cancer

Disappointment as breast cancer drug not approved on NHS

The breast cancer drug trastuzumab emtansine (also known as Kadcyla) will not be made routinely available on the NHS following a failure to reach an agreement on price between the National Institute for Health and Care Excellence ...

Oncology & Cancer

R-CHOP benefits older mantle-cell lymphoma patients

(HealthDay) -- In older patients with mantle-cell lymphoma, a rituximab-based chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) followed by maintenance therapy with rituximab ...

Medications

Roche probed over faulty drug-safety reporting

Swiss pharmaceutical giant Roche is under investigation over a failure to properly report adverse drug side-effects, the European Medicines Agency (EMA) said on Thursday.